References
- 1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56:185-229.10.1124/pr.56.2.615169927
- 2. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34: 106-35.10.1002/med.2128023494977
- 3. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685-96.10.1200/JCO.2005.08.78916234530
- 4. Sardao, VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol. 2009;25:227-43.10.1007/s10565-008-9070-118386138
- 5. Torres VM, Simic VD. Doxorubicin-Induced Oxidative Injury of Cardiomyocytes – Do We Have Right Strategies for Prevention? In: M. Fiuza (ed). Cardiotoxicity of Oncologic Treatments. London: Intech Open; 2012.
- 6. Zhang J, Cui X, Yan Y, Li M, Yang Y, Wang J, et al. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. Am J Transl Res. 2016;8:2862-75.
- 7. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, et al. Pharmacokinetic/pharmacodynamic modelling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res. 2010;16:4946-57.10.1158/1078-0432.CCR-10-1439339097120732963
- 8. Hong B, Lui VWY, Hui EP, Ng MH, Cheng, SH, Sung FL, et al. Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Invest New Drugs. 2011;29:401-10.10.1007/s10637-009-9356-z20013349
- 9. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs. 2009;18:77-87.10.1517/1354378080256725019053884
- 10. Sliwinska J, Dudka J, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, et al. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2+ balance protein levels. Oxid Med Cell Longev. 2012:article ID 890826.10.1155/2012/890826336221122666522
- 11. Minotti G, Licata S, Saponiero A, Menna P, Calafiore AM, Di Giammarco G, et al. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite. Chem Res Toxicol. 2000;13:1336-41.10.1021/tx000143z11123976
- 12. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006;141:312-2210.1104/pp.106.077073147543116760481
- 13. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23:15-25.10.1007/s10565-006-0140-y17009097
- 14. Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang J et al. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res. 2001;61:145-52.
- 15. Matysiak W, Dudka J, Korga A, Zięba J, Syroka I, Dawidek-Pietryka K, et al. Effect of tirapazamine on oxidative stress and metabolic parameters in skeletal muscle of rats treated with classic anticancer drugs. Ann UMC Sec DDD. 2010;XXIII(1):12.
- 16. Ross MF, Kelso GF, Blaikie FH, James AM, Cochemé HM, Filipovska A, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc). 2005;70:222-30.10.1007/s10541-005-0104-515807662